Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Julie Park
COG Phase I Consortium
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Lurie Children'S Hospital-Chicago
Chicago, Illinois, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Columbia University Medical Center
New York, New York, United States
- Oregon Health and Science University
Portland, Oregon, United States
- Baylor College of Medicine
Houston, Texas, United States
- Seattle Children'S Hospital
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2008
- Primary completion
- 28 Feb 2010
- Completion
- —
- Last update posted
- 24 Feb 2014
- Registered enrollment
- 27
- Registry id
- NCT00622414
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.